Company news

Cabaletta Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 27, 2023

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

November 5, 2023

Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis

November 5, 2023

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

October 29, 2023

Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201

October 1, 2023

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

August 29, 2023

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

August 21, 2023

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

August 9, 2023

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

July 23, 2023

Cabaletta Bio to Present at the Jefferies Healthcare Conference

May 30, 2023

Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares

May 21, 2023

Cabaletta Bio Announces Proposed Public Offering of Common Stock

May 16, 2023

Cabaletta Bio Announces Pricing of Public Offering of Common Stock

May 16, 2023

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis

May 15, 2023

Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting

May 1, 2023

Cabaletta Bio Receives FDA Fast Track Designation for CABA-201

April 30, 2023

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

April 24, 2023

Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus

March 30, 2023

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 15, 2023

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

February 27, 2023

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

Cabaletta Bio Announces $35 Million Offering

December 7, 2022

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

October 10, 2022

Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases

October 10, 2022

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

October 5, 2022

Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference

September 25, 2022

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

September 9, 2022

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

August 28, 2022

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

August 10, 2022

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

May 17, 2022

Cabaletta Bio to Present at the H.C. Wainwright Global Investment Conference

May 16, 2022

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

May 1, 2022

Cabaletta Bio to Present at the 21st Annual Needham Virtual Healthcare Conference

April 5, 2022

Cabaletta Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

March 16, 2022

U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART

February 28, 2022

Cabaletta Bio to Participate in the Cowen Virtual 42nd Annual Health Care Conference

February 27, 2022

Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer

January 10, 2022

Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 9, 2022

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Conference

January 2, 2022

Cabaletta Bio Reports Top-line Biologic Activity Data from Two Lowest Dose Cohorts in DesCAARTes™ Trial in Patients with Mucosal Pemphigus Vulgaris

December 13, 2021

Cabaletta Bio to Participate in Upcoming Investor Conferences in November

November 8, 2021

Cabaletta Bio Expands Executive Leadership Team with Appointments of Samik Basu, M.D. to Chief Scientific Officer and Heather Harte-Hall, MSc. to Chief Compliance Officer

November 8, 2021

Cabaletta Bio Reports Third Quarter 2021 Financial Results and Provides Business Update

October 31, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 50 decks. Every deck is listed under its year.